ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
Dow Jones
39,056.39
0.44%
US Dollar vs MXN
16.9054
-0.01%
Brent Oil
83.515
0.78%
Bitcoin
61,489.00
-1.36%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Taysha Gene Therapies Inc (TSHA)

  7. Taysha Gene Therapies Inc (TSHA) Noticias

TSHA Taysha Gene Therapies Inc

2.38
-0.10 (-4.03%)
Fuera de horario
Última actualización: 15:55:17
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Taysha Gene Therapies Inc TSHA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.10 -4.03% 2.38 15:55:17
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.48 2.31 2.48 2.38 2.48
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/5/202415:05GLOBETaysha Gene Therapies to Release First Quarter 2024..
03/5/202415:05GLOBETaysha Gene Therapies Announces Inducement Grant Under..
02/5/202407:00GLOBETaysha Gene Therapies Announces Regenerative Medicine..
05/4/202407:00GLOBETaysha Gene Therapies Announces Inducement Grant Under..
20/3/202412:30APSAnother Biotech Steals The Show Following Major Clinical..
19/3/202415:01GLOBETaysha Gene Therapies Reports Full Year 2023 Financial..
19/3/202406:27IHMARKETNEWSUS Index Futures Decline Ahead of Federal Reserve Meeting,..
14/3/202415:26GLOBETaysha Gene Therapies to Release Full-Year 2023 Financial..
01/3/202416:08GLOBETaysha Gene Therapies Announces Inducement Grant Under..
29/2/202407:00GLOBETaysha Gene Therapies Announces Updates to TSHA-102 Clinical..
15/2/202415:01GLOBETaysha Gene Therapies Provides Update on Deprioritized..
09/2/202415:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202407:00GLOBETaysha Gene Therapies Announces Inducement Grant Under..
22/1/202407:00GLOBETaysha Gene Therapies Announces Poster Presentation on..
10/1/202407:06EDGAR2Form 8-K - Current report
10/1/202407:00GLOBETaysha Gene Therapies Announces First Pediatric Patient..
05/1/202407:00GLOBETaysha Gene Therapies Announces Inducement Grant Under..
20/12/202315:21EDGAR2Form 8-K - Current report
20/12/202315:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
19/12/202306:30PRNUSTrinity Capital Inc. Provides $40 Million Term Loan to..
29/11/202307:00GLOBETaysha Gene Therapies Announces Expanded Eligibility in..
15/11/202315:29EDGAR2Form 8-K - Current report
14/11/202315:47EDGAR2Form 8-K - Current report
14/11/202315:08GLOBETaysha Gene Therapies Reports Third Quarter 2023 Financial..
07/11/202307:00GLOBETaysha Gene Therapies to Release Third Quarter 2023..
03/11/202315:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202315:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/11/202315:02EDGAR2Form 8-K - Current report
24/10/202307:00GLOBETaysha Gene Therapies Presents New Preclinical In-vitro Data..
10/10/202307:00GLOBETaysha Gene Therapies Announces Two Poster Presentations on..
05/10/202306:00EDGAR2Form DEF 14A - Other definitive proxy statements
26/9/202307:08EDGAR2Form 8-K - Current report
26/9/202307:00GLOBETaysha Gene Therapies Announces Second Patient Dosed with..
21/9/202315:01EDGAR2Form PRE 14A - Other preliminary proxy statements
19/9/202315:52DJNTaysha Gene Therapies to End Development of TSHA-120 After..
19/9/202315:09EDGAR2Form 8-K - Current report
19/9/202315:01GLOBETaysha Gene Therapies Provides Update on TSHA-120 Program in..
11/9/202315:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/9/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
30/8/202315:02EDGAR2Form S-3 - Registration statement under Securities Act of..
29/8/202306:00EDGAR2Form 8-K - Current report
25/8/202315:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
24/8/202307:52DJNTaysha Gets FDA Fast-Track for Rett Syndrome Treatment
24/8/202307:09EDGAR2Form 8-K - Current report
24/8/202307:00GLOBETaysha Gene Therapies Announces Fast Track Designation..
14/8/202307:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202306:29EDGAR2Form 8-K - Current report
14/8/202306:02GLOBETaysha Gene Therapies Reports Initial Clinical Data from..
14/8/202306:00GLOBETaysha Gene Therapies Announces $150 Million Private..
04/8/202315:02EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
TSHA
Taysha Gene Therapies
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados